Cancer cachexia—pathophysiology and management

Abstract

About half of all cancer patients show a syndrome of cachexia, characterized by anorexia and loss of adipose tissue and skeletal muscle mass. Cachexia can have a profound impact on quality of life, symptom burden, and a patient’s sense of dignity. It is a very serious complication, as weight loss during cancer treatment is associated with more chemotherapy-related side effects, fewer completed cycles of chemotherapy, and decreased survival rates. Numerous cytokines have been postulated to play a role in the etiology of cancer cachexia. Cytokines can elicit effects that mimic leptin signaling and suppress orexigenic ghrelin and neuropeptide Y (NPY) signaling, inducing sustained anorexia and cachexia not accompanied by the usual compensatory response. Furthermore, cytokines have been implicated in the induction of cancer-related muscle wasting. Cytokine-induced skeletal muscle wasting is probably a multifactorial process, which involves a protein synthesis inhibition, an increase in protein degradation, or a combination of both. The best treatment of the cachectic syndrome is a multifactorial approach. Many drugs including appetite stimulants, thalidomide, cytokine inhibitors, steroids, nonsteroidal anti-inflammatory drugs, branched-chain amino acids, eicosapentaenoic acid, and antiserotoninergic drugs have been proposed and used in clinical trials, while others are still under investigation using experimental animals. There is a growing awareness of the positive impact of supportive care measures and development of promising novel pharmaceutical agents for cachexia. While there has been great progress in understanding the underlying biological mechanisms of cachexia, health care providers must also recognize the psychosocial and biomedical impact cachexia can have.

Proton Pump Inhibitors in cancer patients: How useful they are? A review of the most common indications for their use

“…They are used at the same or higher doses in patients with symptoms of cranial hypertension related to brain or spinal metastases (Bradley and Mehta, 2004) and during radiotherapy on these sites. Other common uses are as adjuvant therapy in pain management (Mitra and Jones, 2012) and as treatment of cancer-related cachexia (Suzuki et al, 2013). In many of these conditions steroids are added to other drugs.…”

A new formula for calculating standard liver volume for living donor liver transplantation without using body weight

“…This does not make sense, since the body weight that is the most physiological and reliable for estimating the required graft volume is unknown. When introducing the concept of SLV to liver resection for the treatment of malignant diseases, a similar dilemma occurs, since a loss of body weight is a typical symptom of patients with malignant disease or patients who are receiving chemotherapy [8,9]. These conditions highlight the need for a new formula that does not use 6 body weight.…”

Effects of nutritional intervention in head and neck cancer patients undergoing radiotherapy: A prospective randomized clinical trial

“…The advantage in prostate cancer is less obvious (7). Suzuki et al (8) reviewed an in-depth description of cancer-related malnutrition pathophysiology. The well-being of the patient may largely be influenced by a good nutritional status (9).…”